Global Pneumonia Therapeutics Market Insights Forecasts to 2030

• The Pneumonia Therapeutics Market Size was valued at USD 2.60 billion in 2021.
• The Worldwide Market Share is growing at a CAGR of 8.9% from 2022 to 2030
• The Global Pneumonia Therapeutics Market Size is expected to reach USD 4.10 billion by 2030
• Asia Pacific is expected to grow the fastest during the forecast period

The global Pneumonia Therapeutics market is expected to reach USD 4.10 billion by 2030, at a CAGR of 8.9% during the forecast period 2022 to 2030. A significant contributing driver is the rise of pneumococcal illness. The prevalence of both community-acquired and ventilator-associated bacterial pneumonia has significantly increased over time.

Market Overview

Pneumonia treatments are used to treat and prevent people with the disease. Pneumonia is an infection that damages people's lungs, particularly the alveoli. Pus or fluid accumulates in the alveoli. Fever, chills, a cough, and breathing difficulties are all signs of pneumonia in a person. In addition, influenza, SARS-CoV-2, and respiratory syncytial virus (RSV) are additional typical causes of viral pneumonia. Streptococcus pneumoniae is another often seen cause of bacterial pneumonia (pneumococcus).

Report Coverage

This research report categorizes the market for Pneumonia Therapeutics market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Pneumonia Therapeutics market. Recent market developments and competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the Pneumonia Therapeutics market.

COVID 19 Impact

Several companies' businesses, including preclinical and clinical testing of microbiome-based therapies and diagnostics, have been significantly impacted by COVID-19 and may continue to be. Because of the rising incidence of infectious diseases and the rising older population with weakened immune systems, it is predicted that the worldwide pneumonia therapeutics market would rise significantly in the future years. Also, it is anticipated that increased research and development efforts by a number of industry participants in the creation of pharmaceuticals and therapeutic agents will accelerate market expansion from 2023 to 2030.

Driving Factors

Throughout the forecast period, an increase in pneumonia cases is anticipated to fuel the market for pneumonia treatments. Furthermore, the market is anticipated to develop in the coming years due to an increase in the prevalence of community-acquired pneumonia, particularly in younger people. Also, rising prevalence shows unmet clinical needs, which will drive up demand for anti-pneumonia drugs in the years to come. Also, it is anticipated that an increase in R&D focused on treatment methods will fuel market expansion. Over the projection period, it is projected that a spike in investments in the development of innovative products that may be utilised as pneumonia treatments would generate lucrative prospects for the market's growth.

Restraining Factors

The development of the worldwide pneumonia therapeutics market during the forecast period may be constrained by a shortage of qualified medical professionals who are unable to treat patients with the proper therapies.

Market Segmentation

• In 2021, the Vaccines segment is holding the dominance over the forecast period.

Based on the product, the global pneumonia therapeutics market is segmented into Drugs, Branded, Quinolones, Aminopenicillins, Macrolides, B-lactamase Inhibitors, Cephalosporins, Tetracyclines, Glycopeptides, Generics, Vaccines, Oxygen Therapy. Among these, the vaccines segment is holding its dominance over the forecast period. The high annual cost of pharmacological therapy and the inadequate insurance coverage are to blame for the extraordinary demand. The desire for preventative therapy is a result of the rise in resistant strains and the high death and morbidity rates linked to pneumococcal infection. The 5-year immunisation schedule, high preventative rates of these vaccines, and growing regulatory agency support for vaccination are all anticipated to create profitable growth possibilities.

Over the projected period, oxygen therapy is anticipated to rise at a moderate rate. This can be linked to the increase in randomised controlled trials for evaluating the efficacy of oxygen therapy in intensive care units. In addition, the need for oxygen treatment to treat pneumococcal disease is driven by the high clinical urgency to develop methods for effective management, which are essential in minimising consequences.

Throughout the projection period, it is anticipated that the pharmaceuticals segment will continue to rise steadily. The introduction of generic medications to the market is responsible for this constant growth. Growth prospects are improving as a result of recent patent expirations of branded pharmaceuticals, the affordability of generics, and rising regulatory pressure on physicians in emerging nations to prescribe generics.

• In 2021, the Prevention Vaccines segment is going to dominate the market over the forecast period.

On the basis of distribution channel, the global pneumonia therapeutics market is segmented into Hospitals, Pharmaceutical Stores, and Others. Among these, the prevention vaccines segment is going to dominate the market over the forecast period because experienced experts are available to treat pneumonia, more outpatients and inpatients are choosing hospitals. Also, it is projected that during the forecast period, hospitals will invest more money in implementing novel pneumonia treatments approaches for the general population. A further factor driving the growth of the pneumonia therapeutics market is the increase in the use of new and effective medications for the condition.

Regional Segment Analysis of the Pneumonia Therapeutics Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is dominating the market over the forecast period.

Among all other regions, North America is dominating the market over the forecast period. This highlights the necessity for the creation of advanced generation treatments and can be ascribed to the growing elderly population as well as the rise in adult and paediatric multidrug resistance. As a result, players in the global market are increasing their R&D spending and concentrating on new product development efforts. Moreover, numerous government programmes for the diagnosis, treatment, and prevention of pneumonia have had a favourable effect across North America.

Throughout the projection period, Asia Pacific is anticipated to exhibit exponential growth with the highest CAGR. Pneumococcal disease prevalence, unmet patient needs, rising instances of antibiotic resistance, and an increase in illnesses weakening the immune system are all contributing factors to this growth.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global Pneumonia Therapeutics market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• AstraZeneca
• Lilly
• F. Hoffmann-La Roche Ltd.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma
• Lupin
• Merck & Co., Inc.
• Pfizer Inc.
• GSK plc
• Hikma Pharmaceuticals PLC
• Cipla Inc.
• Lupin

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at global, regional, and country levels from 2019 to 2030. Spherical Insights has segmented the global Pneumonia Therapeutics market based on the below-mentioned segments:

Pneumonia Therapeutics Market, By Product

• Drugs
• Branded
• Quinolones
• Aminopenicillins
• Macrolides
• B-lactamase Inhibitors
• Cephalosporins
• Tetracyclines
• Glycopeptides
• Generics
• Vaccines
• Oxygen Therapy

Pneumonia Therapeutics Market, By Distribution Channel

• Hospitals
• Pharmaceutical Stores
• Others

Pneumonia Therapeutics Market, Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of Middle East & Africa